WillItSurvive
Medical technology and health companies · United States

Natera

natera.com ↗

Natera runs genetic tests for cancer monitoring, prenatal screening, and organ transplant health.

Hard to displace
Assessed 22 July 2026 · Evidence as of 22 July 2026
Strong structural protection; the business model survives ai pressure.
On the recordSince 22 July 2026 · Checkable from Q3 2026 · Every call on the record Checkpoint: FIND early-cancer-detection study finishes enrollment, aimed at 2027 launch
The call

Natera is growing fast on Signatera volume with courts and Medicare on its side, while cash losses and collection delays remain the thing to watch.

Natera makes blood tests that spot cancer early or track treatment by finding tumor DNA in the bloodstream. Competitors like Labcorp and Invitae tried to copy the work but lost court cases, and now have to pay Natera 30% royalties through 2026, which protects Natera's sales. AI tools cannot replace Natera because they cannot run a certified lab, get insurance approval, or use Natera's private dataset of 250,000 tumor samples. The main risk to watch is slower cash collection from insurance companies if Medicare changes how it pays for these tests, which could strain cash flow even as sales keep growing.

Why
01
AI pressure: None apparent. AI can't run a CLIA lab, draw blood, or replace Natera's 250k-tumor dataset; Natera uses AI internally for assay design. Could AI do the core job? Unlikely.
02
Bigger players: Guardant Health. Guardant is racing to win its own tumor-informed MRD coverage decisions, the same lane where Natera already holds Medicare backing. Could a giant copy it? No, they are blocked.
03
What protects it. A court-ordered 30% royalty on Labcorp/Invitae, Medicare coverage for Signatera, and a tumor-informed workflow rivals can't easily copy.
What would change this call
CMS bundled-pricing rollout effect on Signatera days-sales-outstanding in Q2/Q3 2026 earnings. Would show reimbursement mechanics slowing Natera's cash collections despite revenue growth.
Guardant Health announces new tumor-informed MRD coverage decision or contract win. Would show a peer closing Natera's coverage gap in MRD testing.
FIND early-detection study enrollment completion and results, targeted Q3 2026. Would show whether Natera's next growth platform is on track for 2027 launch.
Key numbers
  • Q1 2026 revenue $696.6M, up 38.8% YoY (2026-05-06)
  • Signatera oncology tests up 55% YoY in Q4 2025 (2026-01-10)
  • Cash of $1.09B vs. just $80.3M debt (2026-05-06)
Named risks
  • CMS bundled-pricing implementation delays causing modest DSO step-up in Signatera collections. Severity: medium
  • Continued net losses ($208.2M FY2025) despite revenue growth, reflecting heavy reinvestment. Severity: medium
  • FIND early cancer detection study enrollment slipping past Q3 2026 target, delaying 2027 launch. Severity: medium
  • Stock trading near all-time high ($288.04 in past 52 weeks) increases sensitivity to any earnings miss. Severity: medium
  • Inivata patent case could be refiled after October 2025 dismissal without prejudice. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
Labcorp (via Invitae/ArcherDx)losing toLost MRD patent suit, court ordered 30% ongoing royalty to Natera, April 8, 2026
Guardant HealthcontestingDirect tumor-naive vs tumor-informed MRD rival, no shown share erosion as of July 2026
InivatacontestingNatera patent suit dismissed without prejudice October 2025 after 1,036 days; refiling possible
NeoGenomicscontestingNamed defendant in Natera ctDNA MRD ('454 patent) litigation, ongoing as of 2026
Questions people ask
Is Natera profitable in 2026?
No. Natera posted a FY2025 net loss of $208.2 million (($1.52)/diluted share), reported February 25, 2026, wider than FY2024's $190.4 million loss, despite revenue growing roughly 35% as the company continues reinvesting in commercial and R&D expansion.
Could AI replace Natera?
Unlikely. Natera runs a CLIA/CAP-accredited lab with Medicare/MolDX coverage and IVDR certification that AI cannot replicate, and it deploys AI (its own foundation models plus an NVIDIA collaboration announced January 11, 2026) as an internal tool to speed diagnostics, not as a substitute for its regulated workflow.
Who is Natera's biggest competitor?
Guardant Health is widely cited as Natera's closest head-to-head rival in cfDNA/MRD testing, using a tumor-naive approach versus Natera's tumor-informed Signatera. Separately, Labcorp (via Invitae/ArcherDx) lost a major MRD patent suit to Natera, with a court ordering a 30% ongoing royalty on April 8, 2026.
Is Natera a safe company to join in 2026?
Financially it looks stable: revenue rose 38.8% YoY to $696.6 million in Q1 2026, FY2026 guidance was raised to $2.74-$2.82 billion on May 6, 2026, and headcount grew 38.5% YoY to 6,140 employees as of December 31, 2025, though the company still posts net losses.
Who owns Natera?
Natera is a publicly traded company on Nasdaq under ticker NTRA, with no parent company. Steve Chapman serves as CEO and co-founder Matthew Rabinowitz is executive chairman, per a January 11, 2026 investor release. Market cap was about $38.26 billion as of July 22, 2026.
Did Natera win its patent fight with Invitae?
Yes. On April 8, 2026 a judge awarded Natera a 30% ongoing royalty on Invitae/ArcherDx's post-injunction MRD-related revenues, resolving a major infringement case in Natera's favor and reinforcing its patent moat around tumor-informed MRD technology.
Timeline
  • 2026-07-22Stock trades at $260.27, market cap ~$38.26B, near 52-week high of $288.04
  • 2026-05-07Q1 2026 call flags FIND ECD enrollment target Q3 2026 and DSO step-up from CMS pricing delays
  • 2026-05-06Q1 2026 revenue $696.6M (+38.8% YoY); FY2026 guidance raised to $2.74-$2.82B
  • 2026-04-08Judge awards Natera 30% ongoing royalty on Invitae/ArcherDx MRD revenues
  • 2026-04-06AACR presentations highlight Latitude assay expansion plans and digital pathology AUROC 0.98 result
  • 2026-02-25FY2025 results: revenue ~$2.3B, net loss $208.2M, test volume 3.53M (+15% YoY)
  • 2026-01-11Natera announces NVIDIA collaboration to scale AI foundation models
  • 2026-01-10Preliminary Q4/FY2025 results show record Signatera growth, oncology tests +55% YoY
  • 2025-12-05Foresight Diagnostics acquisition completed, up to $450M total deal value
  • 2025-08-22Natera launches proprietary AI foundation model platform trained on 250k+ tumor exomes
Head to head
Helix vs Natera
Revision history
22 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
Epic SystemsPro MedicusCochlear Limited
More in Medical technology and health companies →
Sources